J&J's canagliflozin may raise heart risks

01/9/2013 | USA Today · Bloomberg

An FDA panel on Tuesday concluded that Johnson & Johnson's experimental diabetes drug canagliflozin may slightly raise the odds of heart attack, stroke or death as it increased bad cholesterol levels in patients compared with two other diabetes medications. The drug, part of a class known as SGLT2 inhibitors, might help control blood glucose levels in patients with type 2 diabetes, as well as aid in weight loss and lowering blood pressure, a company spokesman said.

View Full Article in:

USA Today · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX